Skip to main content
Premium Trial:

Request an Annual Quote

Geneart Gets Grant to Participate in HIV Vaccine Development

NEW YORK (GenomeWeb News) – Geneart said yesterday that the European Commission has awarded it€300,000 ($470,000) under its 7th Framework Program to participate in a project called "New HIV Vaccines Inducing Broadly Reactive Neutralizing Antibodies."
 
The Regensburg, Germany-based firm will create custom-designed gene sequences for HIV vaccine candidates being developed by the project, which is coordinated by Sanofi Pasteur, the vaccines division of Sanofi-Aventis. The consortium behind the project includes 15 research groups that have received a total contribution of nearly €12 million from the European Union.
 
Geneart said that its technology would be used to optimize gene sequences for highest yields in the selected production system. In addition, it said it would “systemically analyze the influence of different sequence motives — specific successions of bases in a given gene — on production rates in the laboratory.”

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.